# Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

> **NCT01959945** · PHASE3 · COMPLETED · sponsor: **Protein Sciences Corporation** · enrollment: 219 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flublok® Quadrivalent Influenza Virus Vaccine
- **BIOLOGICAL:** Fluarix Quadrivalent® Influenza Virus Vaccine

## Key facts

- **NCT ID:** NCT01959945
- **Lead sponsor:** Protein Sciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-10
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959945, "Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01959945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*